Full video transcriptClick to expand
Auto-generated transcript of @drtrevorbachmeyer's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00metformin versus MOTC and longevity and diabetes.
- 0:04Listen, okay, first metformin, this disaster that people are using for longevity, it's
- 0:08mechanism is this chemical bludgeon. Let me explain this. It walks into yourselves,
- 0:13finds the mitochondrial ETC electron transport chain, which is your personal energy grid,
- 0:19and kicks over the first and most important component of the entire thing, complex one.
- 0:24And then it induces the state of artificial hypoxia suffocating your power plants.
- 0:28It winds up triggering this panic activation of AMPK. So the short term benefit is glucose uptake.
- 0:34Long term cost, you're chronically starving your mitochondria and training them to be weak,
- 0:39inefficient and sparse. You have less of them. 2022 meta-analysis in the Lancet,
- 0:43healthy longevity confirmed it. metformin users show significant reduction in mitochondrial DNA.
- 0:49And the side effects aren't side effects. You're chemically inducing functional vitamin B12
- 0:54deficiency. You know what that causes? Hyperhomocystinemia. This is a proven neurotoxin that
- 0:59accelerates cognitive decline in vascular decay. Look at MOTC. The mechanism is so badass, it
- 1:05upgrades the operating system. Watch. It translocates to the nucleus and acts as a
- 1:11transcriptional regulator. Its primary target is the folate methionine cycle, the absolute core of
- 1:18one-carbon metabolism. This is the system that's responsible for methylating DNA, synthesizing
- 1:23neurotransmitters, producing glutathione, which is your master antioxidant, right?
- 1:27And generating nucleopepitides for repair. And it also activates AMPK. 2015 cell metabolism,
- 1:32they watch. Here's how badass MOTC is. They fed mice, a high fat, obesogenic diet designed
- 1:38to induce metabolic syndrome. The control group got fat, got sick, diabetes and the treatment group
- 1:45received MOTC. And the result, no weight gain, no insulin resistance. Their physiology was completely
- 1:51untouched, protected. They were literally immune to the disease. metformin doesn't do that. It manages
- 1:56the disease once you have it. MOTC prevents you from getting it in the first place. metformin,
- 2:01through B12 deficiency, raises homocysteine, which shreds your myelin sheath and endothelial lining.
- 2:06MOTC, on the other hand, crosses the blood brain barrier, upregulates BDNF, which is the miracle
- 2:12growth for your brain, enhances CREB signaling and acts as a direct neuroprotectant. One protects
- 2:18your brain, the other helps dismantle it. By the way, cancer thrives on dysregulated glycolysis,
- 2:24specifically the Warburg effect. MOTC promotes healthy oxidative phosphorylation, better functional
- 2:31metabolism. Research in oncogen proves it. It activates AMPK mediated pathways that suppress
- 2:37tumor proliferation. How about this one? Diabetes. MOT, which is what people take
- 2:41metformin for originally. MOTC doesn't lower blood sugar. It makes elevated blood sugar
- 2:47a physiological impossibility. Here's how. The cell is no longer deaf,
- 2:50it's no longer inflamed, and it's no longer starting. It's awake, calm, and powered. The
- 2:55disease has nowhere to live. Comment sugar for all the research. I got you. Never miss.
Metformin vs MOTS-c: what the longevity science actually shows
Quick answer
Metformin's inhibition of mitochondrial complex I and its associated B12 depletion risk are documented pharmacological effects, but the drug has decades of evidence supporting cardiovascular and mortality benefits in type 2 diabetic populations. MOTS-c is a mitochondria-derived peptide with promising preclinical data in metabolic and neuroprotective models, but no approved clinical indication and limited human trial data. Patients managing diabetes or considering peptide therapy should make decisions with a licensed clinician, not based on comparative claims made in short-form social content.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Metformin vs MOTS-c: what the longevity science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Foundational preclinical study (Cell Metabolism) where MOTS-c prevented diet-induced obesity and insulin resistance in mice; no human data.
PubMed
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism
Review summarizing MOTS-c metabolic effects drawn from rodent and cell studies, not human trials.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Metformin vs MOTS-c: what the longevity science actually shows should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Metformin vs MOTS-c: what the longevity science actually shows" from Dr Trevor Bachmeyer. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Metformin's inhibition of mitochondrial complex I and its associated B12 depletion risk are documented pharmacological effects, but the drug has decades of evidence supporting cardiovascular and mortality benefits in type 2 diabetic populations.
The reason this review is not generic is the source wording and the canonical claim label "peptides metformin versus mots c longevity diabetes drtrevorbachmeyer." In this clip, the useful excerpt is: "metformin versus MOTC and longevity and diabetes." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (2015), MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism (2016), and Correlation between mitochondrial-derived peptide (MDP) levels and metabolic states: a systematic review and meta-analysis (2024), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Metformin's inhibition of mitochondrial complex I and its associated B12 depletion risk are documented pharmacological effects, but the drug has decades of evidence supporting cardiovascular and mortality benefits in type 2 diabetic populations.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Metformin's inhibition of mitochondrial complex I and its associated B12 depletion risk are documented pharmacological effects, but the drug has decades of evidence supporting cardiovascular and mortality benefits in type 2 diabetic populations. MOTS-c is a mitochondria-derived peptide with promising preclinical data in metabolic and neuroprotective models, but no approved clinical indication and limited human trial data. Patients managing diabetes or considering peptide therapy should make decisions with a licensed clinician, not based on comparative claims made in short-form social content.
- Metformin's inhibition of mitochondrial complex I is real pharmacology, but it has 60-plus years of safety data and evidence of mortality benefit in type 2 diabetics (Campbell et al., 2017, Diabetes Care).
- B12 deficiency from long-term metformin use is a documented, manageable risk. The ADA recommends periodic B12 monitoring, not discontinuation based on this concern alone.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Metformin's inhibition of mitochondrial complex I is real pharmacology, but it has 60-plus years of safety data and evidence of mortality benefit in type 2 diabetics (Campbell et al., 2017, Diabetes Care).
- B12 deficiency from long-term metformin use is a documented, manageable risk. The ADA recommends periodic B12 monitoring, not discontinuation based on this concern alone.
- The 2015 Cell Metabolism mouse study (Lee et al.) on MOTS-c and metabolic syndrome is real and promising, but mouse models do not translate directly to human disease prevention.
- No human clinical trial has demonstrated that MOTS-c prevents type 2 diabetes or makes elevated blood sugar physiologically impossible. That claim is not supported by any published evidence.
- Both metformin and MOTS-c activate AMPK. The creator calls AMPK activation a 'panic response' in metformin and 'badass' in MOTS-c without explaining the distinction, which undermines the comparison's credibility.
- The cited '2022 Lancet meta-analysis' on mitochondrial DNA reduction could not be independently verified. Uncited or misattributed studies in wellness content are a common credibility problem.
- MOTS-c has no regulatory approval for any indication. Anyone considering it is operating well ahead of the clinical evidence and should consult a licensed clinician.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drtrevorbachmeyer actually say?
He argued that metformin is a "chemical bludgeon" that destroys mitochondria, causes vitamin B12 deficiency, raises homocysteine to neurotoxic levels, and ultimately harms the people taking it. Against that, he positioned MOTS-c, a mitochondria-derived peptide, as something that doesn't just manage metabolic disease but makes it a "physiological impossibility." Big claims. Let's look at what holds up.
He cited a "2022 meta-analysis in the Lancet" linking metformin to reduced mitochondrial DNA, a 2015 Cell Metabolism mouse study on MOTS-c and obesity, and a paper in Oncogene on MOTS-c's anti-tumor properties. He also claimed MOTS-c crosses the blood-brain barrier, upregulates BDNF, and "upgrades the operating system" of cellular metabolism through the folate-methionine cycle.
Does the science back this up?
Partially, and with some serious caveats. The metformin-mitochondria story is real but oversimplified. The MOTS-c excitement is legitimate but almost entirely preclinical. Calling MOTS-c a solution that makes diabetes "impossible" is not something any peer-reviewed paper has established in humans.
Metformin does inhibit mitochondrial complex I. That is settled biochemistry (Foretz et al., 2014, Diabetologia). It does cause B12 deficiency in a meaningful subset of users, and elevated homocysteine from B12 deficiency is associated with cognitive and vascular risk (de Jager et al., 2010, BMJ). Those are real signals worth knowing about, not invented.
MOTS-c is genuinely interesting. The 2015 Cell Metabolism paper (Lee et al.) showed that MOTS-c administration prevented obesity and insulin resistance in mice on a high-fat diet. It does activate AMPK and appears to influence one-carbon metabolism. But mice are not people, and "prevented metabolic syndrome in a mouse model" is a long walk from "immune to the disease."
What did they get wrong (or right)?
The metformin framing is where the video goes off track the most. Calling it a "disaster" ignores 60-plus years of safety data in diabetic populations and evidence that it may reduce all-cause mortality in type 2 diabetics (Campbell et al., 2017, Diabetes Care). The AMPK activation metformin triggers is actually the same pathway the creator praises MOTS-c for. He can't call AMPK activation "badass" in one molecule and a "panic response" in another without explaining why. That inconsistency is a red flag.
He got the B12-homocysteine connection right. The American Diabetes Association recommends periodic B12 monitoring for long-term metformin users precisely because this is a documented risk, not a fringe theory.
The Lancet citation about mitochondrial DNA reduction is harder to verify as described. A 2022 Lancet meta-analysis specifically showing mtDNA reduction in healthy longevity cohorts on metformin does not match any study in the published record this writer could identify. That claim needs a proper citation before it should be treated as established.
Saying MOTS-c "prevents you from getting" diabetes is not a conclusion supported by any human trial. Period. The peptide has not been tested in large-scale human longevity or diabetes prevention studies.
What should you actually know?
Metformin is not perfect, but it is one of the most studied drugs in medicine and remains a first-line treatment for type 2 diabetes for good reasons. Its risks are manageable with monitoring. MOTS-c is a genuinely novel research area, but the science is early, the human data is thin, and no regulatory body has approved it for any indication.
The comparison the video sets up, metformin as poison versus MOTS-c as upgrade, is not one the current literature supports. It is a framing built to sell excitement. If you are on metformin, ask your doctor about B12 levels. That is the actually actionable takeaway. If you are curious about MOTS-c, understand that you would be experimenting well ahead of the evidence curve. Research in this space is ongoing, including human studies on MOTS-c and insulin sensitivity, but results are not in yet.
Telehealth platforms and wellness creators have a responsibility not to frame unproven peptides as superior to established medications for serious conditions like type 2 diabetes. That framing can lead people to abandon treatments that work.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Trevor Bachmeyer · TikTok creator
4.3K views on this video
Metformin versus MOTS-C (longevity & diabetes) #DrTrevorBachmeyer #fitness #gymtok #workoutmotivation #fitnesstips #healthylifestyle #motivationdaily #fittok
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about metformin's inhibition of mitochondrial complex i?
Metformin's inhibition of mitochondrial complex I is real pharmacology, but it has 60-plus years of safety data and evidence of mortality benefit in type 2 diabetics (Campbell et al., 2017, Diabetes Care).
What does the video say about b12 deficiency from long-term metformin use?
B12 deficiency from long-term metformin use is a documented, manageable risk. The ADA recommends periodic B12 monitoring, not discontinuation based on this concern alone.
What does the video say about the 2015 cell metabolism mouse study (lee et al.) on?
The 2015 Cell Metabolism mouse study (Lee et al.) on MOTS-c and metabolic syndrome is real and promising, but mouse models do not translate directly to human disease prevention.
What does the video say about no human clinical trial has demonstrated?
No human clinical trial has demonstrated that MOTS-c prevents type 2 diabetes or makes elevated blood sugar physiologically impossible. That claim is not supported by any published evidence.
What does the video say about both metformin?
Both metformin and MOTS-c activate AMPK. The creator calls AMPK activation a 'panic response' in metformin and 'badass' in MOTS-c without explaining the distinction, which undermines the comparison's credibility.
What does the video say about the cited '2022 lancet meta-analysis' on mitochondrial dna reduction could?
The cited '2022 Lancet meta-analysis' on mitochondrial DNA reduction could not be independently verified. Uncited or misattributed studies in wellness content are a common credibility problem.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Trevor Bachmeyer, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.